AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease

J. Kim, Y. S. Yoon, H. Lee, JinWoo Chang

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Citations (Scopus)

Abstract

The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GAB A driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.

Original languageEnglish
Title of host publicationReconstructive Neurosurgery
PublisherSpringer-Verlag Wien
Pages99-105
Number of pages7
Edition101
ISBN (Print)9783211782040
DOIs
Publication statusPublished - 2008 Jan 1

Publication series

NameActa Neurochirurgica, Supplementum
Number101
ISSN (Print)0065-1419

Fingerprint

Neuralgia
Parkinson Disease
Genes
Diagnosis-Related Groups
Therapeutics
Horns
Chronic Pain
Genetic Therapy
Synapses
gamma-Aminobutyric Acid
Neurotransmitter Agents
Animal Models
Neurons
Membranes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Kim, J., Yoon, Y. S., Lee, H., & Chang, J. (2008). AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. In Reconstructive Neurosurgery (101 ed., pp. 99-105). (Acta Neurochirurgica, Supplementum; No. 101). Springer-Verlag Wien. https://doi.org/10.1007/978-3-211-78205-7_17
Kim, J. ; Yoon, Y. S. ; Lee, H. ; Chang, JinWoo. / AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. Reconstructive Neurosurgery. 101. ed. Springer-Verlag Wien, 2008. pp. 99-105 (Acta Neurochirurgica, Supplementum; 101).
@inbook{200672634529478094c19a00c40d19ca,
title = "AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease",
abstract = "The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GAB A driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.",
author = "J. Kim and Yoon, {Y. S.} and H. Lee and JinWoo Chang",
year = "2008",
month = "1",
day = "1",
doi = "10.1007/978-3-211-78205-7_17",
language = "English",
isbn = "9783211782040",
series = "Acta Neurochirurgica, Supplementum",
publisher = "Springer-Verlag Wien",
number = "101",
pages = "99--105",
booktitle = "Reconstructive Neurosurgery",
edition = "101",

}

Kim, J, Yoon, YS, Lee, H & Chang, J 2008, AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. in Reconstructive Neurosurgery. 101 edn, Acta Neurochirurgica, Supplementum, no. 101, Springer-Verlag Wien, pp. 99-105. https://doi.org/10.1007/978-3-211-78205-7_17

AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. / Kim, J.; Yoon, Y. S.; Lee, H.; Chang, JinWoo.

Reconstructive Neurosurgery. 101. ed. Springer-Verlag Wien, 2008. p. 99-105 (Acta Neurochirurgica, Supplementum; No. 101).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease

AU - Kim, J.

AU - Yoon, Y. S.

AU - Lee, H.

AU - Chang, JinWoo

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GAB A driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.

AB - The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GAB A driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.

UR - http://www.scopus.com/inward/record.url?scp=85052610107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052610107&partnerID=8YFLogxK

U2 - 10.1007/978-3-211-78205-7_17

DO - 10.1007/978-3-211-78205-7_17

M3 - Chapter

SN - 9783211782040

T3 - Acta Neurochirurgica, Supplementum

SP - 99

EP - 105

BT - Reconstructive Neurosurgery

PB - Springer-Verlag Wien

ER -

Kim J, Yoon YS, Lee H, Chang J. AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. In Reconstructive Neurosurgery. 101 ed. Springer-Verlag Wien. 2008. p. 99-105. (Acta Neurochirurgica, Supplementum; 101). https://doi.org/10.1007/978-3-211-78205-7_17